Imatinib mesylate treatment of recurrent meningiomas in preselected patients: a retrospective analysis

Journal of Neuro-Oncology, 05/25/2012

The authors conclude that single–agent imatinib mesylate might be a well–tolerated therapeutic option with high achievement of disease stabilization for preselected patients with recurrent meningiomas. Because of the small cohort, non–randomized design, and highly diverse patient population, they propose future prospective studies to validate the results.

Print Article Summary Cat 2 CME Report